Utilizing an innovative chemical platform to defeat antimicrobial resistance
We tackle the challenges posed by the emergence of antimicrobial resistance (AMR) with a conceptually new approach. We have established a scalable chemical platform for the development of novel antibiotic resistance breakers (ARBs). Our compounds sensitize the pathogen and restore the effectiveness of standard-of-care antibiotics. By circumventing the painstaking process of discovering and developing new antibiotics, we bring forth a more cost-effective approach to confront the emergence of AMR. Allowing pharmaceutical companies to protect decades worth of R&D efforts and billions of euros in development costs, we present them with an attractive value proposition. Our platform enables the fast, high-yield production of ARBs against gram-positive bacteria (GmPcides). Our compounds have displayed effectiveness against two of the most threatening drug-resistant pathogens MRSA and VRE. Moreover, the compounds exhibit a strong in vivo synergy with two of the world’s most essential antibiotics Gentamicin and Vancomycin.